PMID- 11110011
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20191025
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 15
IP  - 6
DP  - 2000 Nov
TI  - Reboxetine in the treatment of bulimia nervosa: a report of seven cases.
PG  - 351-6
AB  - Controlled trials in patients with bulimia nervosa have demonstrated efficacy of 
      antidepressant medications with serotonergic function (e.g. fluoxetine) as well 
      as noradrenergic function (e.g. desipramine). Seven outpatients with bulimia 
      nervosa according to DSM-IV criteria were treated openly with 8 mg of reboxetine, 
      a selective noradrenaline reuptake inhibitor (NRI) over a 12-week period. The 
      patients were assessed with the Structured Clinical Interview for DSM, Clinical 
      Global Impression, 17-item Hamilton Depression Rating scale (HAM-D), Eating 
      Disorder Inventory, Eating Disorders Questionnaire, daily self-ratings of eating 
      behaviour, and the UKU side-effect rating scale. Three patients dropped out 
      prematurely, one after 6 weeks and two after 4 weeks of reboxetine treatment. The 
      reasons for premature attrition were rapid remission in one patient after 2 weeks 
      and constipation, which led to an increase in episodes of laxative intake in two 
      patients. In the total group, the monthly binge eating frequency showed a 
      reduction of 73% and the frequency of vomiting episodes per month decreased by 
      67%. Furthermore, there was a concomitant decrease of depression ratings (HAM-D: 
      from 12.2-6.1). Reboxetine seems to be an option for the treatment of bulimia 
      nervosa.
FAU - El-Giamal, N
AU  - El-Giamal N
AD  - Department of General Psychiatry, University Hospital of Psychiatry, Vienna, 
      Austria.
FAU - de Zwaan, M
AU  - de Zwaan M
FAU - Bailer, U
AU  - Bailer U
FAU - Lennkh, C
AU  - Lennkh C
FAU - Schussler, P
AU  - Schussler P
FAU - Strnad, A
AU  - Strnad A
FAU - Kasper, S
AU  - Kasper S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Morpholines)
RN  - 947S0YZ36I (Reboxetine)
SB  - IM
MH  - Adult
MH  - Bulimia/*drug therapy/psychology
MH  - Feeding Behavior/drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morpholines/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Reboxetine
EDAT- 2000/12/08 11:00
MHDA- 2001/05/01 10:01
CRDT- 2000/12/08 11:00
PHST- 2000/12/08 11:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2000/12/08 11:00 [entrez]
AID - 10.1097/00004850-200015060-00006 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2000 Nov;15(6):351-6. doi: 
      10.1097/00004850-200015060-00006.